WO2011031018A3 - Water-soluble drug delivery system allowing slow release - Google Patents

Water-soluble drug delivery system allowing slow release Download PDF

Info

Publication number
WO2011031018A3
WO2011031018A3 PCT/KR2010/005476 KR2010005476W WO2011031018A3 WO 2011031018 A3 WO2011031018 A3 WO 2011031018A3 KR 2010005476 W KR2010005476 W KR 2010005476W WO 2011031018 A3 WO2011031018 A3 WO 2011031018A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery system
drug delivery
slow release
drug
system allowing
Prior art date
Application number
PCT/KR2010/005476
Other languages
French (fr)
Korean (ko)
Other versions
WO2011031018A2 (en
Inventor
이진호
임성묵
오세행
Original Assignee
한남대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100079550A external-priority patent/KR101283454B1/en
Application filed by 한남대학교 산학협력단 filed Critical 한남대학교 산학협력단
Publication of WO2011031018A2 publication Critical patent/WO2011031018A2/en
Publication of WO2011031018A3 publication Critical patent/WO2011031018A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a drug delivery system allowing slow release of the drug. A drug delivery system according to one embodiment of the present invention comprises an ion complex formed from a drug having a negative charge and a compound comprising multivalent cations. Because of the slow release action, the drug delivery system according to the embodiment is advantageous in that it can not only effectively deliver drugs to local affected areas but can also substantially reduce the frequency of drug therapy and in that it can substantially reduce the inconvenience of patients having to frequently attend hospital in order to treat pathologies and the consequent burden of medical expenses for patients.
PCT/KR2010/005476 2009-09-14 2010-08-19 Water-soluble drug delivery system allowing slow release WO2011031018A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20090086596 2009-09-14
KR10-2009-0086596 2009-09-14
KR1020100079550A KR101283454B1 (en) 2009-09-14 2010-08-17 Water-soluble drug delivery system with sustained release behavior
KR10-2010-0079550 2010-08-17

Publications (2)

Publication Number Publication Date
WO2011031018A2 WO2011031018A2 (en) 2011-03-17
WO2011031018A3 true WO2011031018A3 (en) 2011-07-21

Family

ID=43732906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/005476 WO2011031018A2 (en) 2009-09-14 2010-08-19 Water-soluble drug delivery system allowing slow release

Country Status (1)

Country Link
WO (1) WO2011031018A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1143933A2 (en) * 1999-01-22 2001-10-17 Biodelivery Sciences, Inc. Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
US20070077286A1 (en) * 2003-12-24 2007-04-05 Tsutomu Ishihara Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1143933A2 (en) * 1999-01-22 2001-10-17 Biodelivery Sciences, Inc. Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
US20070077286A1 (en) * 2003-12-24 2007-04-05 Tsutomu Ishihara Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BYUN, E. ET AL.: "Characteristics and Drug Release Control of Crosslinked Poloxamer Hydrogel", J. KOR. PHARM. SCI., vol. 26, no. 3, 1996, pages 201 - 205 *
LA, S. ET AL.: "Controlled Drug Delievery of Ampicillin- Poly-(L-Lactic acid) films for the Treatment of Otitis Media", J. KOR. PHARM. SCI., vol. 24, no. 1, 1994, pages 41 - 48 *

Also Published As

Publication number Publication date
WO2011031018A2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
MX354210B (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof.
WO2010042471A3 (en) Medical devices for delivery of therapeutic agents to body lumens
MX352824B (en) USE OF LEVOCETIRIZINE and MONTELUKAST IN THE TREATMENT OF INFLUENZA, COMMON COLD and INFLAMMATION.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2012109022A3 (en) Medical fluid delivery device programming
ZA201003779B (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
MX2020002465A (en) Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium.
PL2726091T3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MX2019003467A (en) Formulations and methods for vaginal delivery of antiprogestins.
MX365688B (en) Drug delivery systems and methods for treatment of bladder cancer comprising oxaliplatin.
MX2015005798A (en) Combination therapy.
WO2014036556A3 (en) Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
HK1208830A1 (en) Drug delivery device for the treatment of patients with respiratory diseases
MY193694A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
IL215826A (en) Sustained release pharmaceutical composition, process for its preparation, its use for the manufacture of a medicament for the treatment of pain and a tablet comprising it
MX2016011333A (en) Drug delivery systems and methods for treatment of bladder cancer with gemcitabine.
MX2015012315A (en) Use of levocetirizine and montelukast in the treatment of traumatic injury.
EA201391689A1 (en) SYSTEM OF DELIVERY MEDICINE
MX2015011775A (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis.
MX2015009546A (en) Increased dosage of efavirenz for the treatment of cancer.
PH12016500063A1 (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EP2578236A4 (en) PREPARATION OF MICROVESICLE-siRNA COMPLEXES AND USE THEREOF IN AIDS TREATMENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10815563

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10815563

Country of ref document: EP

Kind code of ref document: A2